The absence of institutional selling and presence of coordinated accumulation, especially UBS's near-tripling of shares, suggests growing confidence among large financial players. Traders should monitor for follow-on buying, upcoming clinical trial data, or analyst upgrades as potential catalysts. However, given that all buyers are passive mega-banks, this may reflect index rebalancing rather than active conviction.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $10.44entry
- T+1 · 9mo ago −4.21%α −3.30% · $10.00
- T+5 · 8mo ago −19.06%α −17.85% · $8.45
- T+20 · 8mo ago −36.21%α −28.27% · $6.66
- T+60 · 6mo ago −24.14%α −33.46% · $7.92
How similar events traded
Executive Summary
Three major passive institutional investors, Morgan Stanley, Wells Fargo, and UBS, increased their positions in ImmunityBio (IBRX) during Q4 2024, with UBS doubling its stake and the group collectively adding $4.4M in net new value. Despite a minor valuation dip at Wells Fargo, all moves reflect strong accumulation, concentrated among large financial institutions. This coordinated buying suggests growing institutional confidence in IBRX, potentially signaling sector interest in the company's immuno-oncology pipeline.
Key Financial Metrics
Institutional Positions
Net institutional flow: $4.4M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | ADD | +78.3% | $10.3M | $1.9M |
| Wells Fargo | ADD | +30.4% | $355.0K | -$40.5K |
| UBS | DOUBLED | +290.6% | $4.1M | $2.6M |
Key Facts
- Morgan Stanley increased holdings by 1.76M shares, adding $1.9M in value (total position now $10.3M)
- UBS more than doubled its stake, adding 1.18M shares and increasing position value by $2.6M to $4.1M
- Wells Fargo added 32.3K shares despite a slight drop in total position value from $395K to $355K, likely due to share price movement
- No institutional selling observed in this cluster; 3 buyers, 0 sellers
Financial Impact
3 institutions accumulated $4.4M in net new positions during Q4 2024, increasing total holdings from $10.3M to $14.7M
Risk Factors
- All buyers are passive institutions (mega_passive), reducing the strength of the signal compared to active manager conviction
- Wells Fargo's position value declined slightly despite share increase, indicating possible price pressure or lagging performance in the quarter
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-IBRX-2024-Q4 |
Track record
11 reports on IBRX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $7.11 settles Feb 5
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $7.11 settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $8.93 settles Feb 2
- Oct 14, 20264w ago 8-K Bullish 7/10 Entry $10.00 settles Jan 12
- Aug 4, 202614w ago 8-K Neutral 5/10 Entry $6.95 to $8.63 ▲ +24.17% +24.39% vs SPY
- Jul 6, 202619w ago Insider Cluster Neutral 2/10 Entry $8.76 to $9.44 ▲ +7.76% +5.77% vs SPY
- Jul 1, 202619w ago Insider Cluster Neutral 2/10 Entry $9.44 to $8.52 ▼ −9.75% −12.54% vs SPY
- May 18, 202626w ago 8-K Bullish 5/10 Entry $7.76 to $7.65 ▼ −1.42% −7.71% vs SPY
- Apr 9, 202631w ago 8-K Bullish 8/10 Entry $7.48 to $8.91 ▲ +19.12% +8.34% vs SPY
- Apr 6, 202632w ago 8-K Neutral 4/10 Entry $7.08 to $9.20 ▲ +29.94% +16.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers